Vedana Gustavo, Villarreal Guadalupe, Jun Albert S
Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Clin Ophthalmol. 2016 Feb 18;10:321-30. doi: 10.2147/OPTH.S83467. eCollection 2016.
Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease include loss of corneal endothelial cells and formation of excrescences of Descemet's membrane. Later stages involve all layers of the cornea. Impairment of endothelial barrier and pump function and cell death from oxidative and unfolded protein stress contribute to disease progression. The genetic basis of FECD includes numerous genes and chromosomal loci, although alterations in the transcription factor 4 gene are associated with the majority of cases. Definitive treatment of FECD is corneal transplantation. In this paper, we highlight advances that have been made in understanding FECD's clinical features, pathophysiology, and genetics. We also discuss recent advances in endothelial keratoplasty and potential future treatments.
富克斯内皮性角膜营养不良(FECD)是最常见的角膜营养不良,常导致视力丧失。该病的特征包括角膜内皮细胞丢失和后弹力层赘生物形成。后期累及角膜各层。内皮屏障和泵功能受损以及氧化应激和未折叠蛋白应激导致的细胞死亡促进了疾病进展。FECD的遗传基础包括众多基因和染色体位点,尽管转录因子4基因的改变与大多数病例相关。FECD的确定性治疗方法是角膜移植。在本文中,我们重点介绍了在了解FECD的临床特征、病理生理学和遗传学方面取得的进展。我们还讨论了内皮角膜移植术的最新进展以及未来可能的治疗方法。